APOL1

Across TCGA pan-cancer cohorts, APOL1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated APOL1 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher APOL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated APOL1 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

LUAD, GBM, and COAD are the cancer types where APOL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.212	0.839	.004	20	view →
GBM	DFS	Median	All	0.447	0.211	.012	9	view →
COAD	DFS	Median	IV	0.432	0.944	.012	6	view →
PDAC	OS	Median	III,IV	0.537	1.000	.008	3	view →
LSCC	OS	Quartile	II,III,IV	0.619	0.934	.039	2	view →
UCEC	OS	Quartile	All	0.905	1.000	.048	2	view →
HNSC	DFS	Median	III,IV	0.992	0.913	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

APOL1–LUAD (OS)

Open the LUAD breakdown →